WESTON,
Fla., May 14, 2024 /PRNewswire/ - Apotex Corp.
announced today the launch of Cetrorelix Acetate for Injection
0.25mg, a generic version of Cetrotide® in the United States.
Cetrorelix Acetate for Injection is a synthetic decapeptide with
gonadotrophin-releasing hormone (GnRH) antagonist, indicated for
the inhibition of premature LH surges in women undergoing
controlled ovarian stimulation.
"This launch provides American women access to affordable
fertility treatments," said Christine
Baeder, President, Apotex Corp. "It demonstrates our
unwavering focus on meeting patient needs with high-quality
medication that is more accessible to everyone."
Please refer to the complete Prescribing information here for
information on Warnings and Precautions, Adverse Reactions and
Contraindications.
About Apotex Corp.
Apotex Corp. is a US-based company that sells high-quality,
affordable and complex medicines to patients in the United States. Headquartered in
Weston, Florida, Apotex Corp. and
its global affiliates are committed to supplying patients with an
integrated portfolio of generic, biosimilar and innovative branded
pharmaceutical products.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/apotex-corp-launches-generic-fertility-treatment-injectable-cetrorelix-in-the-united-states-302145060.html
SOURCE Apotex Corp.